ArticleFrontiers in neurology2024
Effects of butylphthalide sodium chloride injection combined with edaravone dexborneol on neurological function and serum inflammatory factor levels in sufferers having acute progressive cerebral infarction.
Article in Frontiers in neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Treatment efficacy of butylphthalide and sodium chloride injection combined with argatroban on neurological function and hemorheological parameters in ischemic stroke.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: For investigating an influence on butylphthalide sodium chloride injection combined with edaravone dextromethorphan on neurological function, serum free radical levels, and serum inflammatory factor levels in sufferers having acute progressive cerebral infarction (APCI). Methods: A cohort of 200 patients, afflicted by APCI and admitted to our healthcare institution between December 2018 through July 2023, were incorporated into this longitudinal prospective analysis. Employing a random number table methodology, the patient cohort was bifurcated into a control group ( Results: Compared with the control (65%), the observation group exhibited a significantly higher effective rate of around 89%. In the observation group, the improvement in NIHSS, and Barthel index scores; inflammatory indexes including hs-CRP, IL-8, and TNF-a; and serum free radical levels including ROS, NO, and SOD in peripheral blood was better than the control group, with significant difference (all P<0.05). Conclusion: The clinical efficacy of edaravone dexborneol combined with butylphthalide sodium chloride injection in the treatment of acute progressive cerebral infarction is precise, which can effectively reduce the level of inflammatory factors and serum free radicals in patients, improve the neurological function of patients, and reduce the damage of cerebral cells, and the safety is high.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.